CLINICAL OUTCOMES OF CHILDREN WITH CYSTIC FIBROSIS TREATED WITH INTRAVENOUS TOBRAMYCIN BASED ON A PHARMACOKINETIC ASSESMENT

被引：0
|
作者：
Abrahamsen, K. [1 ,2 ]
Nielsen, K. G. [3 ]
Petersen, K. L. [4 ]
Milla, C. E. [1 ]
机构：
[1] Stanford Univ, Sch Med, Dept Pediat, Ctr Excellence Pulm Biol, Palo Alto, CA 94304 USA
[2] Univ Copenhagen, Copenhagen, Denmark
[3] Rigshosp, Dept Pediat & Adolescent Med, DK-2100 Copenhagen, Denmark
[4] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA
来源：
PEDIATRIC PULMONOLOGY | 2014年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
222
引用
收藏
页码：294 / 294
页数：1
相关论文
共 50 条
  • [1] Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis
    Massie, John
    Cranswick, Noel
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 2006, 42 (10) : 601 - 605
  • [2] Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis
    Sherwin, Catherine M. T.
    Zobell, Jeffery T.
    Stockmann, Chris
    McCrory, Bradley E.
    Wisdom, Millie
    Young, David C.
    Olson, Jared
    Ampofo, Krow
    Spigarelli, Michael G.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 (01) : 71 - 79
  • [3] Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis
    Catherine M. T. Sherwin
    Jeffery T. Zobell
    Chris Stockmann
    Bradley E. McCrory
    Millie Wisdom
    David C. Young
    Jared Olson
    Krow Ampofo
    Michael G. Spigarelli
    Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41 : 71 - 79
  • [4] Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis
    Klingel, Michelle
    Stanojevic, Sanja
    Tullis, Elizabeth
    Ratjen, Felix
    Waters, Valerie
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2019, 16 (07) : 861 - 867
  • [5] Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis
    Dong, Min
    Rodriguez, Anna, V
    Blankenship, Chelsea A.
    McPhail, Gary
    Vinks, Alexander A.
    Hunter, Lisa L.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2021, 76 (11) : 2923 - 2931
  • [6] Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis
    Hennig, Stefanie
    McKay, Karen
    Vidmar, Suzanna
    O'Brien, Katie
    Stacey, Sonya
    Cheney, Joyce
    Wainwright, Claire E.
    JOURNAL OF CYSTIC FIBROSIS, 2014, 13 (04) : 428 - 434
  • [7] Falsely elevated serum tobramycin concentrations in cystic fibrosis patients treated with concurrent intravenous and inhaled tobramycin
    Elidemir, O
    Maciejewski, SR
    Oermann, CM
    PEDIATRIC PULMONOLOGY, 2000, 29 (01) : 43 - 45
  • [8] Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin in Children with Cystic Fibrosis
    Akkerman-Nijland, Anne M.
    Hagedoorn, Paul
    Rottier, Bart L.
    Grasmeijer, Floris
    Frijlink, Henderik W.
    van Luin, Mathijs
    ter Weijden, E.
    Merkus, Peter J.
    Touw, Daan J.
    Akkerman, Onno W.
    Koppelman, Gerard H.
    PHARMACEUTICS, 2025, 17 (03)
  • [9] EFFECT OF AZITHROMYCIN ON THE RESPONSE TO PULMONARY EXACERBATIONS TREATED WITH INTRAVENOUS TOBRAMYCIN IN PATIENTS WITH CYSTIC FIBROSIS
    Klingel, M.
    Ratjen, F.
    Stanojevic, S.
    Tullis, D. E.
    Nichols, D. P.
    Waters, V. J.
    PEDIATRIC PULMONOLOGY, 2017, 52 : S381 - S381
  • [10] Acute kidney injury in cystic fibrosis patients treated with intravenous colistimethate sodium or tobramycin
    Lipp, Madeline A.
    Crass, Ryan L.
    Fitzgerald, Linda J.
    Patel, Twisha S.
    Simon, Richard H.
    Lenhan, Blair E.
    Han, MeiLan K.
    Jia, Shijing
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (09) : 2516 - 2521
12345